May 10, 2021

Maori News & Indigenous Views

Public begins to question safety of NZ H1N1 vaccine

2 min read

We reported earlier in the month that the Ministry of Health was to roll out its phased A/H1N1 Vaccination (“Celvapan”) campaign beginning in early February. This campaign will target health professionals, pregnant women and children from 6 months to 5 years who are enrolled with GPs who are located in areas with high Maori and Pacific Islander populations.

Unfortunately this approach is being called in to question by some health professionals. The catch is that Baxter International, the manufacturer of the A/H1N1 influenza vaccines, is saying two things, the firs is that

The safety of CELVAPAN in pregnancy and lactation has not been assessed in clinical trials.”

In addition, Baxter’s own documentation on Celvapan (p.2) in children aged between 6 months to 8 years of age says

Limited data are available in children 6 months to 8 years of age.

So where does that leave parents and pregnant women who want to make an informed choice. The government is targeting both with a vaccine whose own manufacturer is unsure of it’s safety in these population groups.

One GP clinic that spoke with said that they were meeting to discuss options but felt that they were being put in a difficult position in terms of telling patients that they should get vaccinated but at the same time not being able to confirm (on behalf of Baxter International) that the vaccine was safe for children under 8 and for pregnant women.

Now, considering that Tamariki Maori are highlighted as high risk and part of the first phase of the Ministry of Health’s programme we feel it is important that we are given more information regarding the safety of this vaccine.

We at have always taken a liberal approach to vaccinations (our tamariki are both fully vaccinated) but this recent information is making it harder for us to make an informed decision and we are looking at some direction from the Government considering the importance of this issue.

Will let you know how we get on.

3 thoughts on “Public begins to question safety of NZ H1N1 vaccine

  1. Continued..
    Dr. Sherri Tenpenny ( ) also elaborates on the deleterious effects of the Squalene Adjuvant in a 2006 article entitled, "FLU SHOTS AND THE NEW ADJUVANTS: BEWARE!" (… An excerpt from Dr. Tenpenny's article can give a better appreciation and understanding of what squalene is capable of in the body…

    "On first blush, squalene seems like a good choice for an adjuvant. Manufactured naturally in the liver, squalene is a precursor for cholesterol. In addition, squalene can be purchased at health food stores in its more commonly known form, “shark liver oil.†However, ingested squalene has a completely different effect on the body than injected squalene. When molecules of squalene enter the body through an injection, even at concentrations as small as 10 to 20 parts per billion, it can lead to self-destructive immune responses, such as autoimmune arthritis and lupus.

  2. Here's a fact to help people make an informed choice….
    Ingrediants of the H1N1 Vaccine include Squalene (MF59) a chemical used to amplify the "effectiveness" of the other chemicals present, by making the body go into an INTENSE STATE OF AUTO-IMMUNE SHOCK.
    Here is what the World Association for Vaccine Education had to say about Squalene (MF59):

    Squalene:C30H50 an Adjuvant

    Too dangerous for human use, Squalene is not licensed for use in the United States. Oil adjuvants like squalene have been ordinarily used to inflict diseases in animals – for experimentation and study. According to anthrax vaccine expert Gary Matsumoto and other reliable sources, the US military used an unlicensed, experimental anthrax vaccination laced with squalene, with disastrous consequences, including Gulf War Sydrome.

    Adverse effects:

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.